Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0034067 (
emphysema
)
11,506
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The objective of this study was to investigate the possible anti-asthma role of
Cetirizine
. Forty asthmatics were randomly divided into two groups. The experimental group had 30 patients. Among them were 10 patients with simple asthma, 5 patients complicated by mild
emphysema
, 6 patients complicated by moderate
emphysema
and 9 patients complicated by severe
emphysema
. Vit-C (control) group had 10 cases, including 2 cases of simple asthma, 6 cases complicated by mild
emphysema
and 2 cases complicated by moderate
emphysema
. All patients had a single oral dose of 5 mg
Cetirizine
or 0.1 g Vit-C blindly. Before and 0.5, 1 hour after their medicines, the resistance of airway (Raw), sGaw and MEFV were examined in all patients on 6200 Plethysmograph. The measured values showed a significant improvement of Raw and sGaw after administration of
Cetirizine
. In half an hour after
Cetirizine
, the Raw decreased by 20.408%, and sGaw increased by 28.249%. In one hour after
Cetirizine
, Raw further decreased by 24.34% and sGaw increased by 41.153% (P < 0.001). The FVC in MEFV increased by 4.96% (P < 0.02) in one hour after
Cetirizine
, but other parameters in MEFV curve (PEF, FEV1, MMEF) had no significant changes. All parameters in control group had no significant changes (P > 0.05). The results indicate that
Cetirizine
could decrease Raw in asthmatics, improve their lung ventilatory function.
Cetirizine
is a new H-receptor antagonist usually used as anti-inflammatory and allergy suppression medication. It is shown that
Cetirizine
is a promising anti-asthma agent in treating bronchial asthma.
...
PMID:[Cetirizine improves the resistance of airway and pulmonary function in patients with asthma]. 938 15